Free Trial

Braskem (NYSE:BAK) Posts Earnings Results, Beats Expectations By $0.27 EPS

Braskem logo with Energy background

Braskem (NYSE:BAK - Get Free Report) posted its quarterly earnings results on Monday. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.03 by $0.27, Zacks reports. Braskem had a negative net margin of 9.88% and a negative return on equity of 439.59%. The company had revenue of $3.60 billion during the quarter, compared to analysts' expectations of $22.86 billion.

Braskem Stock Down 0.7%

Shares of BAK traded down $0.03 during mid-day trading on Friday, hitting $3.61. The company had a trading volume of 780,238 shares, compared to its average volume of 790,710. The business's 50-day simple moving average is $3.65 and its 200-day simple moving average is $4.25. Braskem has a 1-year low of $2.85 and a 1-year high of $7.96. The stock has a market cap of $1.44 billion, a PE ratio of -1.02 and a beta of 1.83.

Analyst Ratings Changes

Separately, Scotiabank cut shares of Braskem from a "sector outperform" rating to a "sector perform" rating in a research note on Monday, March 3rd.

View Our Latest Research Report on BAK

About Braskem

(Get Free Report)

Braskem SA, together with its subsidiaries, produces and sells thermoplastic resins. The company operates through three segments: Brazil, United States and Europe, and Mexico. The Brazil segment produces and sells olefins, including ethylene, polymer and chemical grade propylene, butadiene, and butene-1; benzene, toluene, and xylenes products; fuels, such as automotive gasoline, liquefied petroleum gas, ethyl tertiary-butyl ether, and methyl tertiary-butyl ether; intermediates, such as cumene; aliphatics, aromatics, and hydrogenated solvents; and specialties comprising isoprene, dicyclopentadiene, piperylene, nonene, tetramer, polyisobutylene, and hydrocarbon resins.

Read More

Earnings History for Braskem (NYSE:BAK)

Should You Invest $1,000 in Braskem Right Now?

Before you consider Braskem, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Braskem wasn't on the list.

While Braskem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines